NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Deucravacitinib for treating moderate to severe plaque psoriasis ID3859

Provisional Stakeholder List

Consultees	**Commentators (no right to submit or appeal)**
Company • Bristol Myers Squibb (deucravacitinib) Patient/carer groups • British Skin Foundation • Changing Faces • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Association • Psoriasis Help Organisation • South Asian Health Foundation • Specialised Healthcare Alliance Professional groups • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Society for Cutaneous Allergy • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association Others • Department of Health and Social Care • NHS England • NHS North East Essex CCG • NHS Wigan Borough CCG • Welsh Government	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • AbbVie (adalimumab, risankizumab) • Accord Healthcare (methotrexate) • Advanz Pharma (methotrexate) • Almirall (dimethyl fumarate, tildrakizumab) • Amgen (adalimumab, apremilast) • Biogen Idec (adalimumab, dimethyl fumarate, etanercept, infliximab) • Celltrion Healthcare UK (adalimumab, infliximab) • Cipla EU (methotrexate) • Colorama Pharmaceuticals (ciclosporin) • Dexcel-Pharma (ciclosporin)

Consultees	**Commentators (no right to submit or appeal)**
	• Eli Lilly and Company (ixekizumab) • Fresenius Kabi (adalimumab) • Genus Pharmaceuticals (acitretin) • Janssen-Cilag (guselkumab, ustekinumab) • Leo Pharma (brodalumab) • Medac GmbH (methotrexate) • Morningside Healthcare (acitretin, ciclosporin, methotrexate) • MSD (infliximab) • Nordic Pharma (methotrexate) • Novartis Pharmaceuticals UK (ciclosporin, secukinumab) • Orion Pharma (UK) (methotrexate) • Pfizer (etanercept, infliximab, methotrexate) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (adalimumab, etanercept, infliximab, methotrexate) • Teva UK (acitretin, ciclosporin, methotrexate) • Therakind Limited (methotrexate) • UCB Pharma (bimekizumab, certolizumab pegol) • Viatris (ciclosprin) <u>Relevant research groups</u> • British Epidermo-Epidemiology Society • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Skin Treatment & Research Trust <u>Associated Public Health Groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.

